Real‐world evidence on efmoroctocog alfa in patients with haemophilia A: A systematic literature review of treatment experience in Europe
Haemophilia · 2023
DOI: 10.1111/hae.14797 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Haemophilia, 2023. Verfasst von Jan Blatný und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatric Haematology and Biochemistry, University Hospital Brno and Masaryk University, Brno, Czech Republic. Hauptthemen laut MEDLINE: Hemophilia A. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Introduction
The real‐world effectiveness of the efmoroctocog alfa (recombinant FVIII Fc fusion protein, a rFVIIIFc) has been investigated in numerous studies, however, currently, there exists no comprehensive collection of the existing real‐world evidence (RWE) on the performance of prophylactic use of rFVIIIFc.
Aim
The aims of this systematic literature study were to identify, review, evaluate and collate the RWE of prophylactic rFVIIIFc for patients with haemophilia A reported in Europe.
Methods
We searched Medline and Embase from 2014 to February 2022 to identify publications reporting the effectiveness of rFVIIIFc in patients with haemophilia A. The outcomes of interest were annualised bleeding rates (ABR, AjBR, AsBR), injection frequency, factor consumption, adherence, development of inhibitors and quality‐of‐life measures.
Results
46 eligible publications (eight full‐text articles) were included. rFVIIIFc showed a low ABR in patients with haemophilia A. Studies assessing treatment switching from a standard half‐life (SHL) treatment to rFVIIIFc found that the ABR and consumption were reduced in most patients. Studies assessing rFVIIIFc effectiveness reported a median ABR between 0.0 and 2.0 with median injections per week ranging between 1.8 and 2.4 and median doses between 60 and 105 IU/kg/week. Of the studies assessing inhibitor development, only one study reported an incidence of a low titre inhibitor, and no patients developed clinically significant inhibitors. Conclusion rFVIIIFc prophylaxis treatment results in a low ABR across studies in patients with haemophilia A in a European real‐world setting, which correlates with findings from clinical trials assessing the efficacy of rFVIIIFc in patients with haemophilia A.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Paediatric Haematology and Biochemistry, University Hospital Brno and Masaryk University, Brno, Czech Republic.
- EY Godkendt Revisionspartnerselskab, Frederiksberg, Denmark.
- Swedish Orphan Biovitrum AB, Stockholm, Sweden.
- Department for Internal Medicine, Vivantes Hospital Friedrichshain, Haemophilia treatment centre, Berlin, Germany.
- Institute of Experimental Haematology and Transfusion Medicine, University Hospital Bonn, Medical Faculty, University of Bonn, Bonn, Germany.
ORCID-Profile: Signe Baattrup Reitzel, Robert Klamroth
Zitieren
APA
Blatný, J., Nielsen, E. M., Reitzel, S. B., McMillan, A. C., Danø, A., Bystrická, L., Kragh, N., & Klamroth, R. (2023). Real‐world evidence on efmoroctocog alfa in patients with haemophilia A: A systematic literature review of treatment experience in Europe. Haemophilia. https://doi.org/10.1111/hae.14797
Vancouver
Blatný J, Nielsen EM, Reitzel SB, McMillan AC, Danø A, Bystrická L, et al. Real‐world evidence on efmoroctocog alfa in patients with haemophilia A: A systematic literature review of treatment experience in Europe. Haemophilia. 2023. doi:10.1111/hae.14797
BibTeX
@article{Blatn2023,
author = {Blatný, Jan and Nielsen, Emma Munk and Reitzel, Signe Baattrup and McMillan, Annabell Cajus and Danø, Anne and Bystrická, Linda and Kragh, Nana and Klamroth, Robert},
title = {Real‐world evidence on efmoroctocog alfa in patients with haemophilia A: A systematic literature review of treatment experience in Europe},
journal = {Haemophilia},
year = {2023},
doi = {10.1111/hae.14797}
}
EUVIMED